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Protozoana b s t r a c t
Perkinsus marinus is a protozoan parasite that causes ‘‘Dermo’’ disease in the eastern oyster Crasssostrea
virginica in coastal areas of the USA. Until now, intervention strategies against the parasite have found
limited success, and Dermo still remains one of the main hurdles for the restoration of oyster populations.
We adapted a commercial adenosine tri-phosphate (ATP) content-based assay to assess the in vitro pro-
liferation of P. marinus in a 96-well plate format, and validated the method by measuring the effects of
potential anti-proliferative compounds. The sensitivity (1.5–3.1  104 cells/well), linearity (R2 = 0.983),
and signal stability (60 min) support the reliability of the assay for assessing cell proliferation. Validation
of the assay by culturing P. marinus in the presence of increasing concentrations of triclosan showed a
dose–response proﬁle. The IC50 value obtained was higher than that reported earlier, possibly due to
the use of different viability assay methods and a different P. marinus strain. The antibiotics G418 and
tetracycline and the herbicide ﬂuridone were active against P. marinus proliferation; the IC50 of chloram-
phenicol, ciproﬂoxacin, and atrazine was relatively high suggesting either off-target effects or inability to
reach the targets. The validation of the ATP-based assay, together with signiﬁcant advantages of the Perk-
insus culture methodology (homogeneity, reproducibility, and high cell densities), underscores the value
of this assay for developing high-throughput screens for the identiﬁcation of novel leader compounds
against Perkinsus species, and most importantly, for the closely-related apicomplexan parasites.
Published by Elsevier Ltd. on behalf of Australian Society for Parasitology.
D license.1. Introduction
Perkinsus marinus (Perkinsozoa) is a protozoan parasite of mol-
lusks that causes ‘‘Dermo’’ disease in oysters and clams. Described
in the early 1950s as associated with mass mortalities of eastern
oysters (Crassostrea virginica) on the Gulf Coast (Mackin et al.,
1950), the recent expansion of the P. marinus distribution range
in the USA has been associated with global warming and the shell-
ﬁsh trade (Ford and Chintala, 2006; Ford and Smolowitz, 2007). Re-
cently, P. marinus was identiﬁed in the Paciﬁc coast of North
America affecting the oysters Crassostrea corteziensis and Saccostrea
palmula from México (Cáceres-Martínez et al., 2008, 2012). Addi-
tional Perkinsus species affect mollusks worldwide, thereby dam-
aging the shellﬁsheries and the environment (Villalba et al., 2004).Currently, there is no effective treatment for Dermo disease, and
the intervention strategies for management of the resource, such
as restricting transport of oyster stocks, have had limited success
and failed to prevent the expansion of the parasite’s distribution
range (Ford, 1996; Pecher et al., 2008). Selective breeding of dis-
ease-resistant individuals from disease-exposed natural popula-
tions or from laboratory lines selected for resistance to the
protozoan parasite Haplosporidium nelsoni (Haplosporidia) has re-
sulted in partial resistance to Dermo (Debrosse and Allen, 1996;
Ragone Calvo et al., 1997). The use of triploid oyster strains re-
mains a promising alternative (Guo et al., 2000); although non-
resistant to Dermo disease, triploid oysters reach commercial size
before diploid oysters enabling oyster farmers to harvest them
prior mortalities occur. Similarly, off-bottom oyster farming in
Dermo endemic areas such as the Chesapeake Bay (Maryland, Vir-
ginia, USA) allows faster growth and earlier harvests, reducing
exposure to Perkinsus spp. (Fincham, 2010). Because of the
above-mentioned reasons, it is clear that there is an urgent need
for the identiﬁcation of effective anti-Perkinsus drugs. Although
early studies evaluated the efﬁcacy of in vivo and ex vivo chemo-
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1994), it was the development of in vitro culture methods for
P. marinus (Gauthier and Vasta, 1993; Kleinschuster and Swink,
1993; La Peyre et al., 1993) that has greatly facilitated the search
for anti-Perkinsus agents among drugs of well established anti-
microbial, anti-parasitic, and herbicidal properties (Dungan and
Hmailton, 1995; Delaney et al., 2003; Panko et al., 2006; Leite
et al., 2011). Because the P. marinus genome was not available at
the time, however, the molecular mechanisms involved in the inhi-
bition observed remained elusive.
To address the need for identiﬁcation of novel anti-Perkinsus
drugs for both preventive and therapeutic use, we adapted and val-
idated a commercial adenosine tri-phosphate (ATP) content-based
assay in a 96-well plate format by testing P. marinus proliferation
grown under shaking and static conditions, and in the presence
of inhibitors of metabolic pathways likely to be conserved among
parasites and microalgae. This rational target selection was based
on the Chromalveolata hypothesis, under which Perkinsus and
other non-photosynthetic relatives of both dinoﬂagellates and api-
complexans, share a photosynthetic ancestor via a secondary endo-
symbiosis with a red alga, raising the possibility that these lineages
retain cryptic plastids (reviewed in Keeling, 2010). Enzymes in-
volved in plastid pathways in apicomplexans have been recognized
as promising drug targets (Fichera and Roos, 1997; Soldati, 1999;
Aboulaila et al., 2012; Biot et al., 2012; Botte et al., 2012). Although
the presence of a relic plastid in Perkinsus is still under debate,
Perkinsus has key metabolic functions associated with this orga-
nelle (reviewed in Fernández Robledo et al., 2011). Accordingly,
and based on the available information about plastid-related gene
products currently being investigated as potential drug targets in
apicomplexan parasites and the identiﬁcation of related sequences
in the P. marinus draft genome, we evaluated the effect(s) of herbi-
cidal, anti-bacterial, and anti-parasitic drugs on in vitro prolifera-
tion of P. marinus. Among the possible drugs candidates, we
selected triclosan, an anti-bacterial and anti-fungal agent previ-
ously reported to inhibit Perkinsus proliferation (Lund et al.,
2005; Stelter et al., 2007), several anti-Plasmodium drugs (Good-
man et al., 2007), and ﬂuridone, a herbicide that targets phytoene
desaturase (PDS), an enzyme involved in the indirect pathway for
abscisic acid (ABA) synthesis and carotenoid biosynthesis, and al-
ready established as present in P. marinus (Fernández Robledo
et al., 2011), and the widely-used herbicide atrazine (Jowa and
Howd, 2011). The results support that the optimized ATP-based as-
say format will constitute a useful tool for the identiﬁcation of no-
vel effective chemicals for intervention against Dermo disease.
2. Materials and methods
2.1. Materials
The antibiotics chloramphenicol (CAM), ciproﬂoxacin, clinda-
mycin, G418 (gentamicin), tetracycline, the herbicide atrazine (6-
chloro-2,4-diamino-1,3,5-triazine), and the anti-bacterial/-fungal
triclosan [5-chloro-2-(2.4 dichlorophenoxy)-phenol] were pur-
chased from Sigma–Aldrich (St. Louis, MO); the herbicide ﬂuridone
(SC-235160)(1-Methyl-3-phenyl-5-[3-(triﬂuoromethyl)phenyl]-
1,4-dihydropyridin-4-one Fluridone) was purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). We chose to carry out
this study with P. marinus given that the draft genome (http://
www.ncbi.nlm.nih.gov/genome/?term=perkinsus%20genome), and
a transcriptome (Joseph et al., 2010) are available for this species,
and that these resources should facilitate the interpretation and
characterization of drug inhibition mechanisms. Additionally, the
availability of ﬂuorescent mutants (Fernández-Robledo et al.,
2008) should facilitate both ex vivo and in vivo evaluation of the
drugs in host-parasite interaction studies.2.2. Characterization of P. marinus cultures by ﬂow cytometry
Cultures of P. marinus PRA-240 (American Type Culture Collec-
tion, USA, http://www.atcc.org/) (P. marinus wild type; PmWT) and
P. marinus PRA-240 MOE[MOE]:GFP (green ﬂuorescent protein)
(Fernández-Robledo et al., 2008) (accession number ATCC PRA-
393) (P. marinus-GFP; PmGFP) were maintained as reported else-
where (Gauthier and Vasta, 1995). Both PmWT and PmGFP cultures
were seeded at 2  106 cells/ml (50 ml) either in 250 ml Erlen-
meyer ﬂasks and kept at 28 C in an incubator ﬁtted with orbital
shaking (110–120 rpm), or in static cultures using 75 cm2 (50 ml)
vented ﬂasks in a 28 C microbiology incubator. Shaken and static
cultures were sampled daily over a period of two weeks, and ana-
lyzed by ﬂow cytometry [BD Biosciences AccuriC6™ Flow Cytome-
ter (BD, Billerica, MA)] for SSC (side scatter, cell granularity or cell
complexity) versus FSC (forward scatter, cell diameter).2.3. ATP-based P. marinus viability assay in a 96-well plate format
PmWT (100 ll, 2.0  106 cells/ml) cell suspension was serially
diluted (twofold) in a 96-well plate (white OptiPlateTM-96, Perk-
inElmer Life Sciences, Boston, MA). The ATP contained in the sam-
ples was then quantiﬁed using ATPlite assay kit following
manufacturer’s recommendations (PerkinElmer). We also in-
cluded wells with the standard ATP control (twofold serial dilu-
tion of the stock solution; 50 lM). Control wells included cells
incubated in culture medium. Signal stability of ATPlite with cul-
tured P. marinus cells was calculated at all the cell densities as-
sayed over a 120-min period. In another experiment, both
PmWT and PmGFP cultures were sampled each by directly taking
100 ll of the culture and by taking the volume corresponding to
200,000 cells based on OD600. The resulting luminescence was
quantiﬁed in a VersaMax ELISA Microplate Reader running Soft-
Max Pro Microplate Data Acquisition & Analysis Software
(Molecular Devices LLC, Drive Sunnyvale, CA).2.4. Perkinsus marinus growth-inhibition assay
Biological triplicate cultures of PmGFP were grown in sterile
CulturPlate-96 (PerkinElmer) plates (100 ll; 2.0  106 cells/ml).
Perkinsus marinus cells were exposed to the antibiotics ciproﬂox-
acin; (75.2; 150; 300.8; 601.8; 1203; 2407; 4814 lM), clindamy-
cin (0.173; 1.73; 17.3; 1733; 1733 lM), G418 (18; 36; 72.1;
144.2; 288.5; 577.4; 1154 lM), tetracycline (25.9; 51.9; 103.9;
207.9; 415.9; 831.8; 1663.5 lM), CAM (309.5; 619; 1238; 2476;
3095; 3714; 4950 lM), the herbicides atrazine (40; 80; 160;
320; 640; 1280; 2561 lM) and ﬂuridone (18.9; 37.9; 75.9;
151.8; 303.7; 607.4; 1214.7 lM), which theoretically targets the
P. marinus PDS (PmPDS) (GenBank XP_002765827.1 and
XP_002772671.1), and triclosan (21.6; 43.2; 86.4; 172.7; 345.4;
690; 1381 lM). Stock solutions were prepared in water (cipro-
ﬂoxacin, clindamycin, G418), 100% ethanol (CAM, tetracycline,
ﬂuridone), or DMSO (atriazine), and diluted in water to reach
the concentrations indicated above (ﬁnal concentration of ethanol
and DMSO was 1% or less). Control wells included solvent alone
(DMSO, ethanol, or water), the test drug with no cells, and solvent
with cells. The effect of the drugs on P. marinus proliferation was
evaluated using the ATPlite assay at days 2, 4, and 8 post-expo-
sure to the selected drugs. Readings for each concentration were
normalized to the control wells with each solvent (100% activity).
The IC50 was calculated from the dose–response curve using
Prims6 (sigmoidal) (Graphpad Software, Inc). In a replicate exper-
iment, potential changes in P. marinus trophozoite morphology at
the IC50 concentrations were monitored by ﬂuorescence micros-
copy and ﬂow cytometry.
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3.1. Characterization of PmWT and PmGFP cultures by ﬂow cytometry
When PmWT and PmGFP were cultured with shaking, ﬂow
cytometry analysis revealed similar cell density proﬁles for both
(Fig. 1). During the ﬁrst three days of culture, cell size ranges ex-
panded for both PmWT and PmGFP, leading to a noticeable in-
crease in the range of cell sizes with two P. marinus populations
clearly identiﬁed by day 5 (Fig. 1). After seven days, the large cell
population in PmWT was no longer detectable, and the density
plot resembled the initial proﬁle, while for PmGFP the large cell
population remained clearly visible (20% of the total counts) at
this time point, and it took an additional 24 h to reach the start-
ing density plot (data not shown). Overall, cell densities increased
throughout the log phase until the end of the experiment, with
faster growth rates as the populations shifted to smaller cell size
and reduced complexity (days 5–7 for PmWT, and days 5–13 for
PmGFP) (data not shown). Replication of this experiment in static
cell cultures revealed two discrete cell populations at days 4–5
(Fig. 1). In 12–13 days-old shaken cultures both PmWT and
PmGFP trophozoites had gone through a full cycle of palintomy,
as revealed by the population expansion with prevalence of large
cells (58–75%) followed by a shift into the small cell population
(95%). In contrast, the large cell population was hardly noticeable
in static cultures, and never reached the cell densities measured
in the shaken cultures.
3.2. ATP content assay development
The ATP-content based assay consistently enabled the detection
of 1.25  104 P. marinus cells/well, with a lower detection limit of
1.5–3.1  104 cells/well (Fig. 2a). The signal stability decreased
over time, and this was more noticeable at high cell densities. At
cell densities at or below 2.5  105 cells/well, however, the loss
of luminescence was almost negligible over a 120 min period
(Fig. 2b). Within the 1.0  106–6.2  104 cells/well range there
was a strong correlation (R2 = 0.983) between relative lumines-
cence units (RLU) and P. marinus cell number (Fig. 2c). Both PmWTFig. 1. Flow cytometry characterization of Perkinsus marinus PRA-240 grown under sha
selected points (1, 5, 8, and 12 days) of the studied time series. SSC (side scatter, cell grand PmGFP cell populations grown in standard culture medium
showed strong linear correlation of OD600 and cell count
(R2 = 0.997; 0.988, respectively) (data not shown). As assessed by
ATPlite, ATP levels in P. marinus cultures increased over time both
on a volume (100 ll aliquot) and cell number (2  105 cells) basis.
Analysis of 100 ll samples taken during the ﬁrst week of PmWT
cultures revealed a gradual increase of ATP levels, reaching a pla-
teau at day 8–10, followed by a sharp increase on day 13
(Fig. 2d). When measured on a cell number basis (2  105 cells/
sample) ATP levels also increased over time, ranging from 1 to
6 lM (0.5–3.0 pM/cell) (data not shown).
3.3. Perkinsus marinus growth-inhibition assay
The chemicals tested on P. marinus cultures produced a typical
dose–response inhibition curve (Fig. 3). P. marinus proliferation
was inhibited on the lg/ml range by ﬂuridone and triclosan,
the two most potent inhibitors (Fig. 3). On day 4 cultures P. mari-
nus trophozoites were sensitive to CAM (IC50 = 2,246 lM), cipro-
ﬂoxacin (IC50 = 567 lM), G418 (IC50 = 60 lM, day 8), tetracycline
(IC50 = 127 lM), ﬂuridone (IC50 = 38 lM), atrazine (IC50 = 1,687 -
lM), and triclosan (IC50 = 94 lM). However, clindamycin, a bacte-
rial translation blocker that is also toxic to Plasmodium in the nM
range, had no effect on P. marinus proliferation even at 1733 lM.
The IC50 values for most compounds assayed varied depending
on which day post challenge the viability was assessed; in the
cases of G418, the difference was 5.0-fold (Fig. 3). Ciproﬂoxacin
showed growth-inhibition on day 4 (Fig. 3), whereas at day 8
some stimulation of proliferation was observed at low concentra-
tions (75.2; 150 lM; data not shown). For tetracycline, only a
stimulatory effect on proliferation at lower concentrations was
observed after day 4 (Fig. 3). Density plot analysis of the ﬂuri-
done-exposed cells revealed a shift toward larger diameter cells,
while for triclosan the shift was toward small diameter cells
(Fig. 4a). Further, cells treated with triclosan were characterized
by a change from a uniform distribution of the ﬂuorescence
throughout the cell (Fig. 4b) to uneven distribution (Fig. 4c),
whereas the untreated cells showed a uniform ﬂuorescence dis-
tribution (Fig. 4d).ken and static conditions. M1 corresponds to the second population of cells from
anularity or cell complexity) versus FSC (forward scatter, cell diameter).
Fig. 2. ATP-based assay development in 96-well format for Perkinsus marinus. (a) Sensitivity of the assay. (b) Temporal range of the assay. Luminescence was measured every
15 min over a period of 75 min and then at 120 min. (c) Regression between RLU and P. marinus cell number. (d) Time course of P. marinus PRA-240 culture using the ATP-
based assay. Perkinsus marinus cultures were followed over time using the ATP-based assay using both 100 ll sampled directly from the culture (squares) and the equivalent
to 200,000 cells (circles). RLU, relative luminescence units.
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As a ﬁrst step in our quest to develop a high-throughput assay
that would be suitable for the discovery of novel anti-parasitic
compounds, we adapted a standard ATP content-based assay in a
96-well plate format to assess the in vitro proliferation of P. mari-
nus, a protozoan parasite closely related to the Apicomplexa, and
validated the method by measuring the effects of selected anti-
proliferative chemicals. Since the Perkinsus culture methodology
was established, several methods have been used to calculate Perk-
insus cell densities. These include optical density (Gauthier and
Vasta, 1995), CellTiter 96 Aqueous Non-radioactive Cell Prolifera-
tion Assay based on Tetrazolium (Promega Corporation, Madison,
WI) (Dungan and Hmailton, 1995; Elandalloussi et al., 2005), and
Fluorescent AlamarBlue assay (Life Technologies, Grand Island,
NY) (Stelter et al., 2007); these assays take considerable longer
time (hours versus minutes) than the ATP-based assay (Elan-
dalloussi et al., 2005; Stelter et al., 2007). We adapted a commer-
cial ATP content-based assay to estimate proliferation and
cytotoxicity of cultured Perkinsus cells in response to drugs and
biological compounds. ATP is a marker for cell viability; it is pres-
ent in all metabolically active cells and the cell concentration de-
clines very rapidly upon cells undergoing cell death or apoptosis
(Kangas et al., 1984; Lundin et al., 1986). Direct measure of ﬂuores-
cence is also an alternative method to the ATP-based assay,
however, it would have required further optimization (results
not-shown), and it would have precluded from future P. marinus
strain comparison since PmGFP is the only strain constitutively
expressing GFP (Fernández-Robledo et al., 2008). The sensitivity,
linearity, and signal stability of the ATP-based assay supports its
reliability for assessing cell proliferation; in addition, its simplicity
(results were generated within 15–25 min) makes it suitable for
the future development that can eventually be expanded into ahigh-throughput assay (HTS) for drug discovery in 1536-well
plates where 200,000 cells would have to be ﬁtted in 7–10 ll (Chen
et al., 2011). It should be kept in mind that our study optimized
and validated the ATP-based assay in P. marinus, a species that does
not spontaneously sporulate in culture. Whether the ATP-based as-
say performs equally well in Perkinsus spp. that readily sporulate in
culture (Coss et al., 2001a,b; Casas et al., 2002) was outside the
scope of this study and remains to be tested.
The repertory of available anti-Perkinsus drugs has gradually in-
creased over the past few years (Leite et al., 2011), although it is
still very limited as compared to that for protozoan parasites of
medical relevance (Goodman et al., 2007; Chen et al., 2011; Grim-
berg and Mehlotra, 2011; Monzote and Siddiq, 2011). The selection
of potential inhibitory drugs for P. marinus proliferation in earlier
studies was determined by its taxonomic placement, which has
been repeatedly revised as the criteria for phylogenetic analysis
evolved (Mackin et al., 1950; Mackin and Ray, 1966; Levine,
1978; Goggin and Barker, 1993; Siddall et al., 1997; Kuvardina
et al., 2002). Since Perkinsus was initially considered a fungus, tet-
racycline, bacitracin, and gramicidin were interrogated as inhibi-
tors of parasite enlargement in Ray’s ﬂuid thioglycollate medium
(RFTM) (Ray, 1966). Later on, an apparent close relationship to
the Apicomplexa was the rationale for testing anticoccidial drugs
(Perkins, 1976; Levine, 1978; Calvo and Burreson, 1994). Following
the establishment of P. marinus in culture, antibacterials and
antimycotics commonly used to maintain axenic cultures were
shown effective against Perkinsus (Dungan and Hmailton, 1995).
In the studies described herein, we implemented a rational
approach for the selection of drug candidates that might inhibit
P. marinus proliferation on the basis of its evolutionary history
within the Chromalveolata; under this hypothesis Perkinsus shares
a photosynthetic ancestor via a secondary endosymbiosis with a
red alga, raising the possibility that these lineages retain cryptic
Fig. 3. Growth inhibitory activity against P. marinus PRA-393. Biological triplicate cultures were grown in sterile 96-well plates (100 ll; 2.0  106 cells/ml) and cells were
exposed to the antibiotics ciproﬂoxacin, clindamycin, G418, tetracycline, CAM, the herbicides atrazine and ﬂuridone, and triclosan. Control wells included solvent alone, the
test drug with no cells, and solvent with cells. The effect of the drugs on P. marinus proliferation was evaluated using the ATPlite assay at days 2, 4, and 8 (day 9 for triclosan)
post-exposure to the selected drugs. Readings for each concentration were normalized to the control wells with each solvent (100% activity). The IC50 was calculated from the
dose–response curve using Fit Boltzman (sigmoidal).
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recognized as promising drug targets (Aboulaila et al., 2012; Biot
et al., 2012; Botte et al., 2012). Indeed, in silico analysis of the
P. marinus genome draft has revealed putative components of plas-
tid-associated metabolic pathways (reviewed in Fernández Roble-
do et al., 2011). Consequently, we tested drugs amenable to affect
both speciﬁc plastid pathways (triclosan, ﬂuridone, atrazine) and
DNA replication/protein synthesis (ciproﬂoxacin, clindamycin,
G418, tetracycline).
We ﬁrst validated the ATP-based assay by including triclosan,
an anti-bacterial and anti-fungal previously shown to inhibit
P. marinus proliferation (Lund et al., 2005; Stelter et al., 2007).
The IC50 for triclosan we determined was higher than the range re-
ported earlier using different viability assay methods (Lund et al.,
2005; Stelter et al., 2007) (Table 1). The aminoglycoside antibiotic
G418, which inhibits the elongation step in both prokaryotic and
eukaryotic cells (Waitz et al., 1974) and CAM, a broad-spectrum
antibiotic that inhibits translocation steps of protein synthesis
(Wilson, 2011) inhibit P. marinus proliferation (Dungan and Hma-
ilton, 1995) although these studies were carried out in different
P. marinus strain/isolate (Table 1). When compared to this study,
we found differences in susceptibility to G418 and CAM; whether
these differences are methodological or strain – dependent rise
interesting questions regarding drug resistance in Perkinsus andwarrants further investigation. In addition to preventing Perkinsus
trophozoite enlargement in RFTM (Ray, 1966), our study showed
that tetracycline inhibits P. marinus proliferation in vitro. Perkinsus
marinus trophozoites are also sensitive to ciproﬂoxacin at higher
concentrations (458 lM) than Plasmodium (60–80 lM) (Goodman
et al., 2007). In apicomplexans it is believed that ciproﬂoxacin
interferes with the gyrases involved in the replication of plastid
DNA (Biot et al., 2012; Botte et al., 2012); the annotation of the
P. marinus genome also contains numerous gyrases (e.g.
XP_002786436.1), which could be the target of ciproﬂoxacin,
although at this point we cannot rule out an off-target effect.
Based on our ﬂow cytometric analysis of the in vitro Perkinsus
cell cycle and in previous studies (Dungan and Hmailton, 1995;
Stelter et al., 2007; Leite et al., 2011), we determined the IC50 at
2, 4, and 8 days post-challenge. Certainly, we found that with the
exception of ﬂuridone and G418 for which the inhibitory effect
at high-medium concentrations was clearly visible on day 2, the
inhibitory effect(s) of most drugs tested became apparent at day
4. Whether the ability of the parasite to survive inside the oyster
hemocytes has been compromised by the drug treatment would
require a more comprehensive study, and it was outside the scope
of this work.
It has been reported that P. marinus is sensitive to herbicides
(Stelter et al., 2007) (Table 1), and a similar study was carried
Fig. 4. Effect of triclosan on P. marinus. Perkinsus marinus PRA-393 cultures were
grown in the presence of drugs for 9 days and then evaluated at days 2, 4, and 8
post-exposure to the drugs. Although most drugs clearly affected the viability of the
protozoan, their action did not result in changes detectable by ﬂow cytometry
indicating that both diameter and complexity were not substantially affected
during the time examined. In the case of triclosan there was a clear shift of the ﬂow
cytometry plot toward lower size (a) and the ﬂuorescence shifted from being
observed in all the trophozoites (b) to be concentrated in one side of the cell (c)
compared to untreated cells (d). FSC (forward scatter, cell diameter).
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that P. marinus is sensitive to both ﬂuridone and atrazine. Fluri-
done is a widely used herbicide that in plants targets PDS, an en-zyme involved in carotenoid biosynthesis. Mutations of PDS have
been associated with resistance to the herbicide (Arias et al.,
2006). Treatment of P. marinus with ﬂuridone resulted in a reduc-
tion of proliferation and the size ranges in the trophozoite popula-
tion, but could not be associated to any obvious cell phenotype.
What is the target and the biological functions affected by this
compound in Perkinsus remains an open question since it appears
that PmPDS in not expressed in trophozoites under standard cul-
ture conditions (Joseph et al., 2010) and PmPDS
(XP_002765827.1), which appears to have a full coding sequence,
it is not predicted to have the bipartite signal typical of proteins
targeted to the plastid. Triazine derivatives such as atrazine are
used as herbicides targeting the photosynthetic system in plants
(Shimabukuro and Swanson, 1969). They are also used as anti-
microbials by targeting the dihydrofolate reductase (DHFR) of
opportunistic microorganisms (Bag et al., 2010). The DHFR con-
verts dihydrofolate into tetrahydrofolate, which is required for
the de novo synthesis of purines, thymidylic acid, and certain ami-
no acids. Perkinsus is not photosynthetic and consequently it does
not harbor a plastoquinone-binding protein in the photosystem II
susceptible to be targeted by triazine derivatives. However, like
apicomplexans, for which dihydrotriazine derivatives inhibit the
enzyme DHFR (Bag et al., 2010), the P. marinus genome encodes
for putative PmDHFR genes (GenBank GG677709, GG684603) as
potential candidates to be targeted by triazine derivatives. The lack
of inhibition at day 8 by atrazine raises interesting questions
regarding the stability of atrazine in the P. marinus culture. Using
a Pseudomonas atrazine chlorohydrolase sequence (Govantes
et al., 2010) to interrogate the P. marinus genome for the presence
of enzymes involved in the atrazine degradation pathways, we
identiﬁed a putative P. marinus atrazine chlorohydrolase
(XP_002769211, E-value, 2e-27) indicating that P. marinus might
be able to degrade this herbicide. Pesticides (e.g. atrazine) are pres-
ent in coastal runoffs as a product of agricultural activity, poten-
tially down regulating gene expression in the exposed bivalves
(Boutet et al., 2004; Tanguy et al., 2005). In this context, the de-
tailed analysis of the ﬁne balance between the immunosuppressive
effects of the herbicide on the bivalve and adaptations of the par-
asite to overcome its inhibitory effects might provide further in-
sights into unresolved questions concerning infection prevalence
and mortalities along Dermo endemic areas.
Recent reports, including those from our lab have revealed that
Perkinsus spp. express genes involved in multiple pathways (e.g.
Type II FAS enzymes, Fe–S cluster biosynthesis, heme synthesis,
ABA, shikimate pathway) with a bipartite N-terminal extension,
which is consistent with the presence of a relic plastid (reviewed
in (Fernández Robledo et al., 2011). Triclosan targets the FabI in
the FASII biosynthesis; however, in some Apicomplexa it appears
to target other protein/pathways (Yu et al., 2008; Baschong et al.,
2011). On the other hand, the IC50 of atrazine was very high com-
pared to other reports in protozoan parasites (Kumar et al., 2011;
Wise et al., 2012) suggesting that we might be documenting off-
target effects rather than ‘‘true’’ targets. Consequently, the ob-
served susceptibility of P. marinus to antibiotics and herbicides at
relatively high concentrations prevents drawing conclusions con-
cerning the nature of the drug targets in the P. marinus putative re-
lic plastid or its associated metabolic pathways. Still, the close
evolutionary history of apicomplexans and perkinsozoans (both
taxa are exclusively parasitic) (Joseph et al., 2010; Fernández Rob-
ledo et al., 2011) highlights the potential of our assay for identify-
ing drugs against components of their shared pathways.
Whether the drugs tested in this study will be effective in treat-
ing or preventing P. marinus infections in bivalves will depend on
the effectual delivery, ability to reach an effective dose in the oys-
ter tissues, toxicity to the bivalve host (Calvo and Burreson, 1994;
Lund et al., 2005), and eventual drug resistance by the parasite.
Table 1
Compounds tested against Perkinsus marinus.
Compound Perkinsus marinus strain IC50 (lM) Viability assay Reference
CAM P. marinus ATCC 50439a 154.6 Tetrazolium-based Dungan and Hmailton (1995)
P. marinus PRA-393 2446 ATPlite This study
Ciproﬂoxacin P. marinus PRA-393 567 ATPlite This study
G418 P. marinus ATCC 50439a 7212 Tetrazolium-based Dungan and Hmailton (1995)
P. marinus PRA-393 60.0 ATPlite This study
Tetracycline P. marinus ATCC 50439a 4158 c Ray (1966)
P. marinus PRA-393 127 ATPlite This study
Triclosan P. marinusb 5–10 SYBR Green I –Propidium Iodine Lund et al. (2005)
P. marinus ATCC 50439a 27.6 alamarBlue Stelter et al. (2007)
P. marinus PRA-393 94 ATPlite This study
Atrazine P. marinus PRA-393 1687 ATPlite This study
Fluridone P. marinus PRA-393 38 ATPlite This study
a Perkinsus cultured in different culture medium.
b Strain not reported.
c Not applicable.
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daunting, due to the inherent toxicity of the chemicals (e.g. triclo-
san and atrazine) in aquatic environments and to the culture meth-
od (oysters are harvested from natural beds or from semi intensive
culture systems), their use in contained settings (sealed water
ponds, hatcheries) could provide opportunities for producing dis-
ease -free oysters for spat for commercial and repopulation pur-
poses. So far experiments have been carried out in laboratory
conditions with treatments of ﬁve oysters per 10 l baths (Calvo
and Burreson, 1994). One way to approach the treatment of oysters
would be to expose them to the compound in non-tidal ponds in a
similar way to what it is done for ‘‘L’afﬁnage en Claires’’ where oys-
ters are maintained for months to acquire the green color and
change the taste (Deslous-Paoli et al., 1982; Turpin et al., 1999).
After the treatment, oysters would complete the growth directly
in the ponds or in open culture parks where they would reach com-
mercial size before mortalities occur. Finally, sensitivity to CAM,
G418, tetracycline, and ﬂuridone (if it is not an off-target effect)
provides the bases for expanding the molecular tool repertoire in
Perkinsus spp. by incorporating a resistance cassette into the avail-
able transfection plasmid (Fernández-Robledo et al., 2008).
The ﬁndings of our study discussed above, together with the un-
ique advantages of P. marinus with regards to overall ease of cul-
ture, homogeneity, reproducibility, and high cell densities,
underscores the potential of this 96-well plate assay for developing
high-throughput screens aimed at identifying new lead com-
pounds not only against Perkinsus spp. but also against the clo-
sely-related apicomplexans and other protozoan parasites of
human and veterinary relevance.Acknowledgements
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